

October 19, 2016



# Tonix Pharmaceuticals to Host Posttraumatic Stress Disorder (PTSD) Awareness Day

## Key Opinion Leader (KOL) & Investor Event on October 26th

NEW YORK, Oct. 19, 2016 (GLOBE NEWSWIRE) -- [Tonix Pharmaceuticals Holding Corp.](#) (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for PTSD, announced today that it will host an educational event featuring prominent academic physicians to review issues related to understanding and treating PTSD on October 26, 2016 in New York, NY.

This PTSD Awareness Day will feature presentations by Jonathan R.T. Davidson, M.D., professor of Psychiatry and Behavioral Sciences and former Director of the Anxiety and Traumatic Stress Program at Duke University Medical Center, and Thomas A. Mellman, M.D., Professor of Psychiatry and the Director of the Center for Clinical & Translational Science and the Sleep Stress Program at Howard University Medical Center. In addition, Tonix's president and chief executive officer, Seth Lederman M.D., and chief medical officer, Gregory Sullivan, M.D., will provide a corporate update and review of Tonix's PTSD clinical program.

Tonix recently held a successful end-of-phase 2 meeting with the U.S. Food and Drug Administration (FDA) based on positive data from its randomized, double-blind, placebo-controlled Phase 2 AtEase clinical trial evaluating TNX-102 SL (cyclobenzaprine HCl sublingual tablets) in military-related PTSD.

**Event:** PTSD Awareness Day  
**Date:** Wednesday, October 26, 2016  
**Time:** 11:00 am - 2:00 pm (Eastern Time)  
**Location:** Omni Berkshire Hotel - Juilliard Room, New York, NY

A live webcast and subsequent replay of the event will be available on Tonix's website. To access the webcast, please visit the [Events](#) tab of the [Investor Relations](#) section of Tonix's website at [www.tonixpharma.com](http://www.tonixpharma.com).

TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an Investigational New Drug and has not been approved for any indication.

## About Tonix Pharmaceuticals Holding Corp.

Tonix is developing next-generation medicines for common disorders of the central nervous system, with its lead program focusing on PTSD. This disorder is characterized by chronic

disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. This press release and further information about Tonix can be found at [www.tonixpharma.com](http://www.tonixpharma.com).

## Forward Looking Statements

*Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission (the “SEC”) on March 3, 2016, and future periodic reports filed with the SEC on or after the date hereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.*

## Contacts

Jessica Smiley  
Investor Relations  
[investor.relations@tonixpharma.com](mailto:investor.relations@tonixpharma.com)  
(212) 980-9155 x185

Edison Advisors (investors)  
Tirth Patel  
[tpatel@edisongroup.com](mailto:tpatel@edisongroup.com)  
(646) 653-7035

Dian Griesel Int’l (media)  
Susan Forman / Laura Radocaj  
[sforman@dgicomm.com](mailto:sforman@dgicomm.com)  
[iradocaj@dgicomm.com](mailto:iradocaj@dgicomm.com)  
(212) 825-3210



Source: Tonix Pharmaceuticals Holding Corp.